BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ye CP, Qiu CZ, Huang ZX, Su QC, Zhuang W, Wu RL, Li XF. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007; 13(46): 6264-6268 [PMID: 18069771 DOI: 10.3748/wjg.v13.i46.6264]
URL: https://www.wjgnet.com/1007-9327/full/v13/i46/6264.htm
Number Citing Articles
1
Felix H. Shek, Tracy C. W. Lai, Sarwat Fatima, Nikki P. Lee. New Advances on Disease Biomarkers and Molecular Targets in Biomedicine2013; : 57 doi: 10.1007/978-1-62703-456-2_4
2
Jin Long Liu, Xue Jun Zhang, Zhao Zhang, An Hong Zhang, Wei Wang, Jia Hong Dong, Lian-Yue Yang. Meta-Analysis: Prognostic Value of Survivin in Patients with Hepatocellular CarcinomaPLoS ONE 2013; 8(12): e83350 doi: 10.1371/journal.pone.0083350
3
Rebecca Liu, Duane A. Mitchell. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumorsCancer Immunology, Immunotherapy 2010; 59(2): 183 doi: 10.1007/s00262-009-0757-9
4
J. González-Gallego, M.J. Tuñón. Apoptosis: Involvement of Oxidative Stress and Intracellular Ca2+ Homeostasi2009; : 73 doi: 10.1007/978-1-4020-9873-4_4
5
Francesco Godizzi, Federico Armando, Patrizia Boracchi, Giancarlo Avallone, Damiano Stefanello, Roberta Ferrari, Lavinia E. Chiti, Andrea Cappelleri, Clarissa Zamboni, Silvia Dell’Aere, Attilio Corradi, Paola Roccabianca. Survivin, β-catenin, and ki-67 immunohistochemical expression in canine perivascular wall tumors: Preliminary assessment of prognostic significanceVeterinary Pathology 2024;  doi: 10.1177/03009858241246981
6
Süleyman Bayram, Hikmet Akkız, Aynur Bekar, Ersin Akgöllü. The association between the survivin −31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish populationCancer Epidemiology 2011; 35(6): 555 doi: 10.1016/j.canep.2011.01.004
7
Tetsuhiro Tsuruma, Hidekaz Kameshima, Yuji Iwayama, Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Sato, Koichi Hirata. Apoptosome2010; : 305 doi: 10.1007/978-90-481-3415-1_16
8
Giulia Fianco, Claudia Contadini, Alessandra Ferri, Claudia Cirotti, Venturina Stagni, Daniela Barilà. Caspase-8: A Novel Target to Overcome Resistance to Chemotherapy in GlioblastomaInternational Journal of Molecular Sciences 2018; 19(12): 3798 doi: 10.3390/ijms19123798
9
N Charette, C De Saeger, Y Horsmans, I Leclercq, P Stärkel. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanismsCell Death & Disease 2013; 4(1): e471 doi: 10.1038/cddis.2012.200
10
Seong Hwi Hong, Young Ju Lee, Eun Bi Jang, Hyun Ji Hwang, Eun Song Kim, Da Hyeon Son, Sung Yul Park, Hong Sang Moon, Young Eun Yoon. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCCInternational Journal of Molecular Sciences 2023; 25(1): 216 doi: 10.3390/ijms25010216
11
Mahsa Mobahat, Aru Narendran, Karl Riabowol. Survivin as a Preferential Target for Cancer TherapyInternational Journal of Molecular Sciences 2014; 15(2): 2494 doi: 10.3390/ijms15022494
12
Isabel Fabregat. Dysregulation of apoptosis in hepatocellular carcinoma cellsWorld Journal of Gastroenterology 2009; 15(5): 513-520 doi: 10.3748/wjg.15.513
13
Venturina Stagni, Simonetta Santini, Daniela Barilà. A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM KinaseCancers 2012; 4(2): 354 doi: 10.3390/cancers4020354